{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:43:15Z","timestamp":1769640195487,"version":"3.49.0"},"reference-count":20,"publisher":"Walter de Gruyter GmbH","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2024-0556_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Empagliflozin has been used for the treatment of over 100 glycogen storage disease type Ib (GSDIb) patients worldwide since 2019. We aimed to evaluate the effect of empagliflozin treatment on the laboratory and clinical findings of patients with GSDIb in T\u00fcrkiye.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2024-0556_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Included in this multicenter study were 10 patients with GSDIb, and whose demographic, clinical and laboratory data were analyzed retrospectively. Further data for the study were garnered through a survey of patients and caregivers to evaluate the effects of empagliflozin treatment on quality of life (QoL).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2024-0556_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The mean age at which the empagliflozin treatment was started was 73.2 (4\u2013239) months. The mean duration of empagliflozin treatment was 16.9 (8\u201339) months. Glucosuria was identified in eight (80\u202f%) patients undergoing empagliflozin treatment, while urogenital infections were detected in six (60\u202f%) and hypoglycemia in two (20\u202f%). An analysis of neutrophil levels revealed increased absolute neutrophil counts following empagliflozin treatment. Skin and\/or mucosal lesions were noted in nine (90\u202f%) patients prior to the initiation of empagliflozin treatment, but persisted in only one patient following empagliflozin treatment (10\u202f%) (p=0.008). Empagliflozin treatment resulted in a decrease in the frequency of hospitalizations due to infection (p=0.0015). Furthermore, 80\u202f% of the patients reported positive impact on their well-being as a result of the empagliflozin treatment, and 70\u202f% of parents reported improvement in physical performance and activities, in the sleep quality of both the patient and parents, and in mobility.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2024-0556_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study revealed empagliflozin to be effective in improving the neutrophil counts of patients with GSD Ib and in enhancing the QoL of both the patients and their caregivers.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2024-0556","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T16:38:29Z","timestamp":1740587909000},"source":"Crossref","is-referenced-by-count":1,"title":["Effect of empagliflozin treatment on laboratory and clinical findings of patients with glycogen storage disease type Ib: first study from T\u00fcrkiye"],"prefix":"10.1515","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7238-2894","authenticated-orcid":false,"given":"Engin","family":"K\u00f6se","sequence":"first","affiliation":[{"name":"Department of Pediatric Metabolism , Ankara University Faculty of Medicine , Ankara , T\u00fcrkiye"},{"name":"Rare Diseases Research and Application Center , Ankara University , Ankara , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5214-516X","authenticated-orcid":false,"given":"Figen","family":"\u00d6z\u00e7ay","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology and Hepatology , Ba\u015fkent University Faculty of Medicine , Ankara , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7994-4394","authenticated-orcid":false,"given":"Halil \u0130brahim","family":"Ayd\u0131n","sequence":"additional","affiliation":[{"name":"Department of Metabolic Diseases , Ba\u015fkent University Faculty of Medicine , Ankara , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3569-276X","authenticated-orcid":false,"given":"\u00c7i\u011fdem Seher","family":"Kasapkara","sequence":"additional","affiliation":[{"name":"Department of Pediatric Metabolism , Ankara Y\u0131ld\u0131r\u0131m Beyaz\u0131t University, Ankara Bilkent City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0561-2060","authenticated-orcid":false,"given":"Asl\u0131","family":"\u0130nci","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nutrition and Metabolism , Gazi University School of Medicine , Ankara , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4766-300X","authenticated-orcid":false,"given":"Aynur","family":"K\u00fc\u00e7\u00fckcongar Yava\u015f","sequence":"additional","affiliation":[{"name":"Department of Metabolic Disorders , Ankara City Hospital , Ankara , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-3184","authenticated-orcid":false,"given":"Leyla","family":"T\u00fcmer","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nutrition and Metabolism , Gazi University School of Medicine , Ankara , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5880-1113","authenticated-orcid":false,"given":"Fatma Tuba","family":"Emino\u011flu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Metabolism , Ankara University Faculty of Medicine , Ankara , T\u00fcrkiye"},{"name":"Rare Diseases Research and Application Center , Ankara University , Ankara , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"2025022616382005073_j_jpem-2024-0556_ref_001","unstructured":"Bali, DS, El-Gharbawy, A, Austin, S, Pendyal, S, Kishnani, PS. Glycogen storage disease type I. In: Adam, MP, Feldman, J, Mirzaa, GM, et al.., editors. GeneReviews\u00ae. Seattle (WA): University of Washington, Seattle; 1993\u20132024. [Internet] Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1312\/."},{"key":"2025022616382005073_j_jpem-2024-0556_ref_002","doi-asserted-by":"crossref","unstructured":"Dale, DC, Bolyard, AA, Marrero, T, Kelley, ML, Makaryan, V, Tran, E, et al.. Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. Curr Opin Hematol 2019;26:16\u201321. https:\/\/doi.org\/10.1097\/MOH.0000000000000474.","DOI":"10.1097\/MOH.0000000000000474"},{"key":"2025022616382005073_j_jpem-2024-0556_ref_003","doi-asserted-by":"crossref","unstructured":"Derks, TGJ, Venema, A, K\u00f6ller, C, Bos, E, Overduin, RJ, Stolwijk, NN, et al.. Repurposing empagliflozin in individuals with glycogen storage disease Ib: a value-based healthcare approach and systematic benefit-risk assessment. J Inherit Metab Dis 2024;47:244\u201354. https:\/\/doi.org\/10.1002\/jimd.12714.","DOI":"10.1002\/jimd.12714"},{"key":"2025022616382005073_j_jpem-2024-0556_ref_004","doi-asserted-by":"crossref","unstructured":"Veiga-da-Cunha, M, Chevalier, N, Stephenne, X, Defour, JP, Paczia, N, Ferster, A, et al.. Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency. Proc Natl Acad Sci USA 2019;116:1241\u201350. https:\/\/doi.org\/10.1073\/pnas.1816143116.","DOI":"10.1073\/pnas.1816143116"},{"key":"2025022616382005073_j_jpem-2024-0556_ref_005","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnert, SC, Derks, TGJ, Adrian, K, Al-Thihli, K, Ballhausen, D, Bidiuk, J, et al.. Efficacy and safety of empagliflozin in glycogen storage disease type Ib: data from an international questionnaire. Genet Med 2022;24:1781\u20138. https:\/\/doi.org\/10.1016\/j.gim.2022.04.001.","DOI":"10.1016\/j.gim.2022.04.001"},{"key":"2025022616382005073_j_jpem-2024-0556_ref_006","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnert, SC, Derks, TGJ, Mundy, H, Dalton, RN, Donadieu, J, Hofbauer, P, et al.. Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: consensus from an international workshop. Mol Genet Metabol 2024;141:108144. https:\/\/doi.org\/10.1016\/j.ymgme.2024.108144.","DOI":"10.1016\/j.ymgme.2024.108144"},{"key":"2025022616382005073_j_jpem-2024-0556_ref_007","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnert, SC, Gautschi, M, Baker, J, Boyer, M, Burlina, A, Casswall, T, et al.. Empagliflozin for treating neutropenia and neutrophil dysfunction in 21 infants with glycogen storage disease 1b. Mol Genet Metabol 2024;142:108486. https:\/\/doi.org\/10.1016\/j.ymgme.2024.108486.","DOI":"10.1016\/j.ymgme.2024.108486"},{"key":"2025022616382005073_j_jpem-2024-0556_ref_008","doi-asserted-by":"crossref","unstructured":"Wortmann, SB, Van Hove, JLK, Derks, TGJ, Chevalier, N, Knight, V, Koller, A, et al.. Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor. Blood 2020;136:1033\u201343. https:\/\/doi.org\/10.1182\/blood.2019004465.","DOI":"10.1182\/blood.2019004465"},{"key":"2025022616382005073_j_jpem-2024-0556_ref_009","doi-asserted-by":"crossref","unstructured":"Murko, S, Peschka, M, Tsiakas, K, Schulz-J\u00fcrgensen, S, Herden, U, Santer, R. Liver transplantation in glycogen storage disease type Ib: the role of SGLT2 inhibitors. Mol Genet Metab Rep 2023;35:100977. https:\/\/doi.org\/10.1016\/j.ymgmr.2023.100977.","DOI":"10.1016\/j.ymgmr.2023.100977"},{"key":"2025022616382005073_j_jpem-2024-0556_ref_010","doi-asserted-by":"crossref","unstructured":"Guerra, F, Gasperini, S, Bonanomi, S, Crescitelli, V, Pretese, R, Da Dalt, L, et al.. Finding balance between mature and immature neutrophils: the effects of empagliflozin in GSD-Ib. EJHaem 2023;4:551\u20134. https:\/\/doi.org\/10.1002\/jha2.649.","DOI":"10.1002\/jha2.649"},{"key":"2025022616382005073_j_jpem-2024-0556_ref_011","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnert, SC, Venema, A, LaFreniere, J, Schneider, B, Contreras, E, Wortmann, SB, et al.. Patient-reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: an international questionnaire study. JIMD Rep 2023;64:252\u20138. https:\/\/doi.org\/10.1002\/jmd2.12364.","DOI":"10.1002\/jmd2.12364"},{"key":"2025022616382005073_j_jpem-2024-0556_ref_012","doi-asserted-by":"crossref","unstructured":"Lava, SAG, Laurence, C, Di Deo, A, Sekarski, N, Burch, M, Della Pasqua, O. Dapagliflozin and empagliflozin in paediatric indications: a systematic review. Paediatr Drugs 2024;26:229\u201343. https:\/\/doi.org\/10.1007\/s40272-024-00623-z.","DOI":"10.1007\/s40272-024-00623-z"},{"key":"2025022616382005073_j_jpem-2024-0556_ref_013","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnert, SC, Elling, R, Maag, B, Wortmann, SB, Derks, TGJ, Hannibal, L, et al.. Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib. Orphanet J Rare Dis 2020;15:218. https:\/\/doi.org\/10.1186\/s13023-020-01503-8.","DOI":"10.1186\/s13023-020-01503-8"},{"key":"2025022616382005073_j_jpem-2024-0556_ref_014","doi-asserted-by":"crossref","unstructured":"Kaczor, M, Greczan, M, Kierus, K, Ehmke Vel Emczy\u0144ska-Seliga, E, Ciara, E, Pi\u0105tosa, B, et al.. Sodium-glucose cotransporter type 2 channel inhibitor: breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b? JIMD Rep 2022;63:199\u2013206. https:\/\/doi.org\/10.1002\/jmd2.12278.","DOI":"10.1002\/jmd2.12278"},{"key":"2025022616382005073_j_jpem-2024-0556_ref_015","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnert, SC, Rosenbaum-Fabian, S, Schumann, A, Selbitz, AC, Merz, W, Gieselmann, A, et al.. Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib. JIMD Rep 2022;63:303\u20138. https:\/\/doi.org\/10.1002\/jmd2.12295.","DOI":"10.1002\/jmd2.12295"},{"key":"2025022616382005073_j_jpem-2024-0556_ref_016","doi-asserted-by":"crossref","unstructured":"Hexner-Erlichman, Z, Veiga-da-Cunha, M, Zehavi, Y, Vadasz, Z, Sabag, AD, Tatour, S, et al.. Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients. Front Pediatr 2022;10:1071464. https:\/\/doi.org\/10.3389\/fped.2022.1071464.","DOI":"10.3389\/fped.2022.1071464"},{"key":"2025022616382005073_j_jpem-2024-0556_ref_017","doi-asserted-by":"crossref","unstructured":"Halligan, RK, Dalton, RN, Turner, C, Lewis, KA, Mundy, HR. Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre. Orphanet J Rare Dis 2022;17:195. https:\/\/doi.org\/10.1186\/s13023-022-02345-2.","DOI":"10.1186\/s13023-022-02345-2"},{"key":"2025022616382005073_j_jpem-2024-0556_ref_018","doi-asserted-by":"crossref","unstructured":"Makrilakis, K, Barmpagianni, A, Veiga-da-Cunha, M. Repurposing of empagliflozin as a possible treatment for neutropenia and inflammatory bowel disease in glycogen storage disease type Ib: a case report. Cureus 2022;14:e27264. https:\/\/doi.org\/10.7759\/cureus.27264.","DOI":"10.7759\/cureus.27264"},{"key":"2025022616382005073_j_jpem-2024-0556_ref_019","doi-asserted-by":"crossref","unstructured":"Tallis, E, Karsenty, CL, Grimes, AB, Karam, LB, Elsea, SH, Sutton, VR, et al.. Untargeted metabolomic profiling in a patient with glycogen storage disease Ib receiving empagliflozin treatment. JIMD Rep 2022;63:309\u201315. https:\/\/doi.org\/10.1002\/jmd2.12304.","DOI":"10.1002\/jmd2.12304"},{"key":"2025022616382005073_j_jpem-2024-0556_ref_020","doi-asserted-by":"crossref","unstructured":"Rossi, A, Miele, E, Fecarotta, S, Veiga-da-Cunha, M, Martinelli, M, Mollica, C, et al.. Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report. Ital J Pediatr 2021;47:149. https:\/\/doi.org\/10.1186\/s13052-021-01100-w.","DOI":"10.1186\/s13052-021-01100-w"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2024-0556\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2024-0556\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T16:38:35Z","timestamp":1740587915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2024-0556\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":20,"alternative-id":["10.1515\/jpem-2024-0556"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2024-0556","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}